Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tc-99m-annexin V-128

Next Previous
Drug Profile

Tc-99m-annexin V-128

Alternative Names: 99mTc-rhAnnexin V-128; 99mTechnetium-labelled rhAnnexin V-128; rhAnnexin V-128; Tc-99m-recombinant human annexin V-128; Tc-99m-rhAnnexin V-128

Latest Information Update: 29 Sep 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Atreus Pharmaceuticals
  • Developer Advanced Accelerator Applications; INSERM
  • Class Calcium binding proteins; Organotechnetium compounds; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Technetium compounds
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Ankylosing spondylitis; Autoimmune disorders; Cancer; Cardiomyopathies; Cardiovascular disorders; Carotid stenosis; Rheumatoid arthritis; Spondylarthritis

Most Recent Events

  • 29 Sep 2021 Discontinued - Phase-I for Rheumatoid arthritis (Diagnosis, In volunteers) in Canada (IV)
  • 29 Sep 2021 Discontinued - Phase-I/II for Ankylosing spondylitis (Diagnosis) in Switzerland (IV)
  • 29 Sep 2021 Discontinued - Phase-I/II for Cardiovascular disorders (Diagnosis) in France (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top